Please assess the completion status of the following clinical trial:

Trial Title: Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ischemic stroke with symptoms of neurological deficits.~2. Aged 18 to 80 years（including the critical value）.~3. NIH Stroke Scale（NIHSS）scores of 4 to 25（including the critical value）.~4. Treatment within 4.5 hours after stroke onset.~5. The symptoms of stroke last at least 30 minutes without significant improvement before treatment.~6. CT showed negative or signs of early infarction.~7. Informed Consent Form signed by the patients or family (legal representatives) must be provided.~Exclusion Criteria:~1. Patients with premorbid modified Rankin Scale (mRS) score ≥2~2. CT showed multiple infarctions（low density\> 1/3 cerebral hemisphere）.~3. Transient ischemic attack.~4. Epileptic seizure after stroke.~5. Intracranial tumor, arteriovenous malformation and aneurysm.~6. Iatrogenic Stroke.~7. Planned for thrombectomy.~8. Cardioembolism and atrial fibrillation.~9. Myocardial infarction history within 3 months.~10. Severe cerebral trauma or stroke history within 3 months.~11. Patients with systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 100mmHg after anti-hypertension treatment.~12. Intracranial hemorrhage or subarachnoid hemorrhage on baseline.~13. Active visceral hemorrhage.~14. Patients with intracerebral hemorrhage history.~15. Patients with diabetic retinopathy history.~16. Puncture in 1 week which can not be oppressed.~17. Major surgery or severe trauma within 2 weeks.~18. Intracranial surgery, intraspinal surgery or solid organ biopsy within 30 days.~19. Heparin treatment within 48h and increased APTT is above ULN.~20. Using of oral anticoagulant drugs and PT \>15s or INR \>1.7.~21. High risk of acute hemorrhage include platelet count\<10\^9/L.~22. Using of thrombin inhibitors or factor Xa inhibitor with abnormal results of sensitive laboratory examination.~23. Blood glucose \< 2.7 mmol/L or \> 22.2 mmol/L.~24. Pregnancy, lactating or menstrual women.~25. The investigator believes that the patient is not suitable for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Recombinant human urokinase (rhPro-UK)
- Group B (Type: ACTIVE_COMPARATOR): Alteplase(rt-PA)

Based on this trial design, predict the completion outcome and termination type (if applicable).